The director of General American Investors Company, Inc. (GAM), Fbo Trust Sold 2,066 Shares of the Company; ARGOS THERAPEUTICS Has 0.85 Sentiment

Argos Therapeutics, Inc. (NASDAQ:ARGS) Logo

ARGOS THERAPEUTICS INC (ARGS) investors sentiment increased to 0.85 in Q4 2017. It’s up 0.22, from 0.63 in 2017Q3. The ratio is more positive, as 11 institutional investors increased or started new stock positions, while 13 sold and reduced stakes in ARGOS THERAPEUTICS INC. The institutional investors in our database now own: 2.48 million shares, down from 2.64 million shares in 2017Q3. Also, the number of institutional investors holding ARGOS THERAPEUTICS INC in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 8 Reduced: 5 Increased: 5 New Position: 6.

Argos Therapeutics, Inc. (NASDAQ:ARGS) Ratings Coverage

Ratings analysis reveals 0 of Argos Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Argos Therapeutics, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ARGS was included in 2 notes of analysts from February 22, 2017. JMP Securities downgraded the shares of ARGS in report on Wednesday, February 22 to “Mkt Perform” rating. On Wednesday, February 22 the stock rating was downgraded by FBR Capital to “Mkt Perform”.

Bank Of New York Mellon Corp holds 0% of its portfolio in Argos Therapeutics, Inc. for 24,052 shares. Blackrock Inc. owns 7,526 shares or 0% of their US portfolio. Moreover, California Public Employees Retirement System has 0% invested in the company for 94,800 shares. The Switzerland-based Credit Suisse Ag has invested 0% in the stock. Deutsche Bank Ag, a Germany-based fund reported 36 shares.

The stock decreased 67.29% or $0.72 during the last trading session, reaching $0.35. About 6.39M shares traded or 629.38% up from the average. Argos Therapeutics, Inc. (ARGS) has declined 87.69% since April 19, 2017 and is downtrending. It has underperformed by 99.24% the S&P500.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $2.77 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Since December 14, 2017, it had 7 insider purchases, and 1 sale for $368,862 activity. Another trade for 4,000 shares valued at $132,620 was made by Priest Jeffrey W on Thursday, February 8. On Thursday, January 25 BERENS RODNEY B sold $144,716 worth of General American Investors Company, Inc. (NYSE:GAM) or 4,000 shares. 5,800 shares valued at $197,991 were bought by DAVIDSON SPENCER on Friday, December 15. Shares for $7,445 were bought by Majmudar Anang K. on Thursday, February 8. Stark Eugene S had bought 700 shares worth $23,716.

Fbo Trust, the director of General American Investors Co Inc, sold 2,066 shares of the company, worth total $70,765 U.S Dollars, estimated based on $34.3 of a share. Fbo Trust today possess 0.01% of the market cap of the Company.

General American Investors Company, Inc. is a publicly owned investment manager. The company has market cap of $893.84 million. The firm invests in the public equity markets. It has a 5.66 P/E ratio. It invests in growth stocks of companies.

The stock decreased 0.35% or $0.12 during the last trading session, reaching $34.13. About 29,655 shares traded. General American Investors Company, Inc. (NYSE:GAM) has risen 9.16% since April 19, 2017 and is uptrending. It has underperformed by 2.39% the S&P500.

Investors sentiment increased to 2.05 in 2017 Q4. Its up 1.27, from 0.78 in 2017Q3. It improved, as 2 investors sold General American Investors Company, Inc. shares while 18 reduced holdings. 9 funds opened positions while 32 raised stakes. 6.48 million shares or 11.86% less from 7.35 million shares in 2017Q3 were reported. 6,036 were accumulated by Baker Ellis Asset Mngmt Lc. Shaker Financial Svcs Ltd Liability holds 138,422 shares. Stevens First Principles Inv Advsr holds 0.02% or 880 shares in its portfolio. Karpus Mgmt has invested 0.01% in General American Investors Company, Inc. (NYSE:GAM). Citigroup reported 15,129 shares or 0% of all its holdings. Baystate Wealth Mngmt stated it has 0% in General American Investors Company, Inc. (NYSE:GAM). Jacobs Ca reported 7,516 shares or 0.05% of all its holdings. Rivernorth Cap Limited Liability reported 223,737 shares. Pinnacle Assoc Limited invested 0.01% in General American Investors Company, Inc. (NYSE:GAM). Thomas J Herzfeld Advsr Inc holds 2.35% or 186,400 shares. Moreover, 1832 Asset Mngmt Ltd Partnership has 0.02% invested in General American Investors Company, Inc. (NYSE:GAM) for 163,804 shares. The New York-based Overbrook has invested 0.75% in General American Investors Company, Inc. (NYSE:GAM). Rmb Capital Management Lc has 0.01% invested in General American Investors Company, Inc. (NYSE:GAM) for 15,446 shares. Fifth Third Financial Bank has 0% invested in General American Investors Company, Inc. (NYSE:GAM). Kistler has invested 0.06% in General American Investors Company, Inc. (NYSE:GAM).